Future Of Lilly’s Arxxant In Doubt
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly says it is considering options for the investigational diabetic retinopathy treatment after FDA rejected the company's appeal of a recent "approvable" decision.
You may also be interested in...
Lilly Acquires Diabetes Candidates In Deal With Transition Therapeutics
After ending its efforts to develop inhaled insulin, Lilly rebuilds in-house pipeline of diabetes candidates.
Lilly Acquires Diabetes Candidates In Deal With Transition Therapeutics
After ending its efforts to develop inhaled insulin, Lilly rebuilds in-house pipeline of diabetes candidates.
Lilly To Appeal FDA Action On Arxxant Calling For Additional Clinical Trial
Company says Arxxant clinical data package presents a compelling case for the treatment of diabetic retinopathy.